Biopharmaceutical company Intra-Cellular Therapies Inc (Nasdaq:ITCI) on Tuesday announced positive topline results from a Phase 3 trial evaluating CAPLYTA (lumateperone) for the prevention of relapse in patients with schizophrenia.
The study demonstrated that lumateperone significantly delayed relapse compared to placebo. There were 18 relapses (16.4%) in the lumateperone group versus 44 relapses (38.6%) in the placebo group. Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo.
The treatment was generally safe and well-tolerated.
These positive results highlight the potential of CAPLYTA as a maintenance therapy for schizophrenia.
Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC
MHRA approves Efmody for adrenal insufficiency treatment
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD
Chance Pharma reports NMPA acceptance of NDA for investigational respiratory drug CXG87
Altasciences and Certara form strategic partnership to accelerate early drug development
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
NextCell Pharma and FUJIFILM Biosciences launch global MSC research product
ZYUS Life Sciences receives second US pain management patent
MingMed Biotechnology presents QA102 Phase II trial data in intermediate AMD at ARVO 2026